Aurinia Pharmaceuticals Inc.

Equities

AUPH

CA05156V1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 09/07/2024 am IST			5-day change	1st Jan Change
5.63 ^USD	+0.36%		+2.55%	-37.37%

01/07	Aurinia Pharmaceuticals Inc.(NasdaqGM:AUPH) added to Russell Small Cap Comp Value Index	CI
01/07	Aurinia Pharmaceuticals Inc.(NasdaqGM:AUPH) added to Russell 2500 Value Index	CI

Tranche Update on Aurinia Pharmaceuticals Inc.'s Equity Buyback Plan announced on February 15, 2024.

May 02, 2024 at 03:37 pm IST

From February 15, 2024 to March 31, 2024, the company has repurchased 2,373,374 shares, representing 1.64% for $13.19 million. With this, the company has completed the repurchase of 2,373,374 shares, representing 1.64% for $13.19 million under the buyback announced on February 15, 2024.

Latest news about Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc.(NasdaqGM:AUPH) added to Russell Small Cap Comp Value Index	01/07	CI
Aurinia Pharmaceuticals Inc.(NasdaqGM:AUPH) added to Russell 2500 Value Index	01/07	CI
Aurinia Pharmaceuticals Inc.(NasdaqGM:AUPH) added to Russell 3000 Value Index	01/07	CI
Aurinia Pharmaceuticals Inc.(NasdaqGM:AUPH) added to Russell 2000 Value Index	01/07	CI
Aurinia Pharmaceuticals Inc.(NasdaqGM:AUPH) added to Russell 3000E Value Index	01/07	CI
Declaration of Voting Results by Aurinia Pharmaceuticals	15/06	CI
Declaration of Voting Results by Aurinia Pharmaceuticals Inc	15/06	CI
Transcript : Aurinia Pharmaceuticals Inc. - Shareholder/Analyst Call	14/06
ILJIN SNT Co Provides Information to Shareholders of Aurinia Pharmaceuticals	07/06	CI
Aurinia Pharmaceuticals Inc. Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis	05/06	CI
Lucien Selce Sends Letter to Aurinia shareholders	03/06	CI
Aurinia Pharmaceuticals Inc. Presented Results from the Analysis Showing Lupkynis A Cost-Effective Treatment for Lupus Nephritis Presented At National Kidney Foundation's Spring Clinical Meeting 2024	14/05	CI
Lucien Selce Urges Aurinia Pharmaceuticals Board to Take Action to Enhance Shareholder Value	07/05	CI
Transcript : Aurinia Pharmaceuticals Inc., Q1 2024 Earnings Call, May 02, 2024	02/05
Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q1 Revenue $50.3M, vs. Street Est of $47.1M	02/05	MT
Tranche Update on Aurinia Pharmaceuticals Inc.'s Equity Buyback Plan announced on February 15, 2024.	02/05	CI
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI
Aurinia Pharmaceuticals Inc. Reiterates Revenue Guidance for the Fiscal Year 2024	02/05	CI
Aurinia Pharmaceuticals Inc. Announces The U.S. Food & Drug Administration Approves Updated LUPKYNIS® Label to include Long-Term Data from the AURORA Clinical Program	30/04	CI
ILJIN SNT Delivers a Letter to Aurinia Pharmaceuticals	21/03	CI
Aurinia Pharmaceuticals Insider Sold Shares Worth $711,094, According to a Recent SEC Filing	08/03	MT
Aurinia Pharmaceuticals Insider Sold Shares Worth $323,372, According to a Recent SEC Filing	08/03	MT
HC Wainwright Cuts Price Target on Aurinia Pharmaceuticals to $13 From $15, Maintains Buy Rating	22/02	MT
RBC Cuts Price Target on Aurinia Pharmaceuticals to $8 From $13, Keeps Outperform, Speculative Risk	16/02	MT
Sector Update: Health Care Stocks Higher Late Afternoon	16/02	MT

Chart Aurinia Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil (MMF) and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. Its product pipeline includes AUR200 and AUR300.

Sector

Biotechnology & Medical Research

Calendar

09/07/2024 - Leerink Partners Therapeutics I&I and Metabolism Forum

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Aurinia Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.61 USD

Average target price

10.14 USD

Spread / Average Target

+80.80%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AURINIA PHARMACEUTICALS INC.	-37.37%	800M
VERTEX PHARMACEUTICALS INCORPORATED	+18.43%	122B
REGENERON PHARMACEUTICALS, INC.	+19.81%	112B
BIONTECH SE	-23.74%	19.33B
GENMAB A/S	-18.45%	16.17B
BEIGENE, LTD.	-19.97%	15.6B
WUXI APPTEC CO., LTD.	-49.33%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.08%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+7.95%	14B
INSMED INCORPORATED	+126.04%	11.29B

Bio Therapeutic Drugs